Update MEBO Gut Microbiome Study

Click on icon

As we wait for the results from uBiome of Batch #4 of the MEBO Clinical Trial, Dynamics of the Gut Microbiotal in Idiopathic Malodor Production, which explores the microbial basis of systemic malodor and PATM conditions, Irene Gabashvili, PhD., Principal Investigator has written a few posts in her Aurametrix Blog, pointing out various findings as the study unfolds. In her previous posts, Irene observed epulopiscium and blastocystis hominis as potential culprits of conditions in MEBO sufferers. In her most recent post (Sep 4, 2019), she observes a third group of MEBO sufferers (only 10% of participants) with elevated levels of Alloprevotella group of microbes (see figure above), which seem to be making symptoms worse. "This bacteria is an oral bacteria associated with gingivitis and periodontal conditions..."

The Anna Karenina principle (AKP), in the context of metabolic disorders, would mean that an uncompensated deficiency in any one of important enzymes, or presence of any one of pathogenic microorganisms, dooms the person to having the MEBO/PATM symptoms.

We note that neither of microorganisms identified in our study is a true pathogen. These could be opportunistic microbes taking advantage of opportunities not normally available, such as weakened enzymes or disrupted gut microbiota. The microbes we see could be also symbionts of pathogens or indicators of inflammation and dysbiosis.
bhttps://aurametrix.com/blog/akpb

For more indepth explanation on Alloprevotella and the chart above, please refer to the post in Aurametrix.

Irene tells us that this gut microbiome study is the first to pursue the root cause:

Our microbiome trial is the first study where we can actually group participants based on the root cause, independently of their diets (unlike our Biolab and Wishart metabolome studies).

Full paper (Biolab), "Community-led research discovers links between elusive symptoms and clinical tests," on MEBO-Biolab study,Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis : NCT02692495

Full paper (Wishart), "Identifying subtypes of a stigmatized medical condition" on Exploratory Study of Relationships Between Malodor and Urine Metabolomics: NCT02683876

---

MEBO Dynamics of the Gut Microbiota 

in Idiopathic Malodor Production

This MEBO clinical trial is in its final stages of data analysis and will soon publish the conclusion. Meanwhile, the updates on findings by Irene Gabashvili, PhD., Principal Investigator, can be found in the following posts in the Aurametrix Blog:

1. Alloprevotella: September 4, 2019
2. Epulopiscium: August 19, 2019
3. Friends and Stars: August 14, 2019
4. PATM and TMAU: August 5, 2019
5. Feeding microbiomes: July 21, 2019
6. Blood type: June 2, 2019
7. First 41 results: November 21, 2018
8. Press Release: November 28, 2018
9. What we hope to learn: June 27, 2018
10. MEBO Microbiome Study: June 215, 2018
11. Microbes of anti-social odor: March 14, 2018
12. Crowdsourcing precision medicine: February 23, 2018

We are most grateful to uBiome for their very generous research grant and to Irene for her dedication and leadership in this research study.

María

María de la Torre
Founder and Executive Director

A Public Charity
maria.delatorre@meboresearch.com
www.meboresearch.org
www.mebo.com.br/
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)

---

SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.

get New Posts by EMAIL : Enter your email address :

---

A EURORDIS and NORD Member Organization